IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Juno Therapeutics Inc. and Reminds Investors with Losses in Excess of $50,000 to Contact the Firm

IRVINE, CA / ACCESSWIRE / August 30, 2016 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit has been filed against Juno Therapeutics Inc. (“Juno” or the “Company”) (Nasdaq: JUNO). Investors, who purchased or otherwise acquired shares between June 4, 2016 and July 7, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the September 12, 2016 lead plaintiff motion deadline.

If you purchased shares of Juno during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, Juno failed to disclose that a patient died during a clinical trial for its product candidate in May 2016. Juno was thus trading at artificially inflated prices and some insiders sold shares until July 7, 2016. On July 7, 2016, the Company announced the May 2016 death and two additional deaths during clinical trial. The Food and Drug Administration put a hold on the trial. When this information was released to the public, shares of Juno decreased in value.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 444531